Amneal published its Q1 2022 financial results, reporting a 1% increase YoY in net revenue. Amneal announced that it plans to expand into high growth areas including biosimilars and injectables.
Print Page Mail ArticleBioBlast w/e 2 Jun 23
01 JUN 2023 | EU | New indication alert: EC approves Novartis’ Cosentyx® (secukinumab) for HS Novartis announced that the European Commission (EC)...